Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01080365 · ClinicalTrials.gov registry record · Phase 1
Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01080365 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 31 participants.
The verdict
NCT01080365, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Study comparing 2 formulations of bosutinib in healthy subjects.
Interventions
- DRUG SKI-606 (Bosutinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01080365
The ClinicalTrials.gov registry entry for NCT01080365 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SKI-606 (Bosutinib) is the first listed.
NCT01080365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01080365 about?
NCT01080365 is a clinical study titled "Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions". Study comparing 2 formulations of bosutinib in healthy subjects.
What is the current status of trial NCT01080365?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2010-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT01080365?
The interventions under investigation include: SKI-606 (Bosutinib) (DRUG).
Who is sponsoring clinical trial NCT01080365?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.